NCT02025010 2025-04-15
Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
10 trialsNCT02669771 2024-11-21
Long-Term Specified Drug Use-Results Survey for Xtandi Capsule
Astellas Pharma Inc
Completed
NCT04232761 2024-07-17
RAPIT
Bayer
Completed
NCT05549778 2023-07-11
PEACe
Jiangnan University
Phase 1/2 Completed
NCT04962880 2023-04-14
PROSPECT
AstraZeneca
Completed
NCT03247010 2022-11-09
Bone Marrow Suppression and Recovery During Radionuclide Treatment
Rigshospitalet, Denmark
Completed
NCT02207504 2022-01-06
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02346578 2021-09-16
Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.
Osaka City University
Phase 2 Completed
NCT01634061 2020-12-09
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
Novartis
Phase 1 Completed
NCT02361086 2019-02-01
A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
Innocrin Pharmaceutical
Phase 1/2 Completed